Skip to main content
DD logo

DD · DuPont de Nemours, Inc.

Track DD — free
$153.78 -0.92 (-0.59%) At close · Nov 13
Market Cap
$20.38B
Shares
132.53M
Volume · Nov 13 1.11M Avg daily vol (3M) 1.1M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$153.78 Open$155.92 Day$151.79–155.97 52W close$111.36–156.88 Avg vol 30d1.1M Short int3.9M · 2.9% of shares · 4.6d Short vol39% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 9, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $1.87B ▲ 4.1% Net income $123M Diluted EPS $0.91
Nov 3
Earnings call
Raises 2026 guidance after 31% adjusted EPS growth

DuPont raised full-year 2026 guidance to net sales of about $7.19 billion, operating EBITDA of $1.785 billion and adjusted EPS of $7.50, after third-quarter organic growth of 5%, adjusted EPS growth of 31% and margin expansion of 90 basis points.

6 source passages
Broad-based sales growth combined with a continued focus on productivity enabled organic growth of 5%, 90 basis points of margin expansion, 31% adjusted EPS growth, and robust free cash flow conversion in the quarter. As a result of our performance, we are again raising our full year 2026 financial guidance for organic sales growth, operating EBITDA, and adjusted EPS, all at or above the high end of our previously communicated range. We now expect sales to be about $7.19 billion, an increase of $15 million from the midpoint of our prior guidance and at the top end of our prior guidance range. Operating EBITDA is now expected to be $1.785 billion, an increase of $25 million from the midpoint of our prior guidance, reflecting our stronger third quarter results, as well as increased productivity benefits as we exit the year. Our adjusted EPS at the midpoint of $7.50 is a 25-cent increase versus our prior guidance and represents a 22-percent increase compared to the prior year pro forma. This underscores our confidence in DuPont's long-term growth potential and reinforces our focus on allocating capital where we see compelling return opportunities, including investing in our own shares. Open the document at this passage
Nov 3
Current report 8-K
Raises full-year guidance as third-quarter sales and EPS rise

DuPont posted third-quarter 2026 net sales of $1,868 million, up 4%, adjusted EPS of $2.09 and operating EBITDA of $469 million. It raised full-year 2026 adjusted EPS guidance to $7.47 - $7.52 per share and plans a $250 million fourth-quarter share repurchase.

Financial results
6 source passages
DuPont (NYSE: DD) announced its financial results(1) for the third quarter ended September 30, 2026 and again raised financial guidance for the full year 2026. Net sales | $1,868 | $1,795 | 4% | 5% GAAP EPS from continuing operations of $1.24; adjusted EPS of $2.09 GAAP Income from continuing operations of $171 million; operating EBITDA of $469 million we are again raising our full-year financial outlook and now expect organic growth to be about 4.5%, operating EBITDA to be about $1.785 billion and adjusted EPS to be in the range of $7.47 - $7.52 per share Announces intent to repurchase $250 million of shares in the fourth quarter Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$7.06B
Trailing 12 months
Net income (TTM)
$301.00M
Trailing 12 months
Revenue growth YoY
+4.1%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
69.0
Trailing earnings · reciprocal yield 1.5%
FCF yield
3.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.44B
Latest balance sheet
Dividend yield
1.6%
Trailing 12 months
Shares change YoY
-3.5%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
2.9%
Latest settlement · 4.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. DuPont exceeded third-quarter guidance, delivered 5% organic sales growth, expanded operating EBITDA margin, posted substantially higher adjusted EPS, and generated strong cash conversion before raising full-year guidance again. Middle East project delays, currency and inflation headwinds, lower quarterly free cash flow, construction and automotive declines, and PFAS-related risks remain concerns.

Bullish
  • + Full-year 2026 guidance was raised again, with organic growth, operating EBITDA, and adjusted EPS all at or above the previous range’s high end.
  • + DuPont completed a $250 million accelerated share repurchase, substantially completed $100 million of open-market purchases, and plans another $250 million repurchase in the fourth quarter.
  • + The order book increased double digits year over year, supported by customer wins in adhesives, aerospace seals, and desalination.
Bearish
  • − Large Middle East water projects are expected to shift into 2027, and approximately $15 million of revenue was pushed out of the 2026 plan.
  • − Currency reduced consolidated third-quarter sales growth by 1%.
  • − Third-quarter transaction-adjusted free cash flow declined 1% year over year.
  • − Oil and gas inflation created a margin headwind, partly offsetting growth and productivity benefits.
  • − Construction and automotive end markets declined by low single digits, creating a headwind to portfolio growth.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +14%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 93%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +18%
trailing
6-month return +4%
trailing
YTD return +28%
this year
Relative strength +3%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $135 › 200d $139 — 200d above 50d
Institutional flow Distributing
1,066 of 1,142 funds reported for Sep 30 · net -2.6M sh shares · +107 new
Insider flow Distributing
Net -$14.1M over 90 days · 100% sells
Short interest Falling
2.92% of shares out · ▼ -17.4% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1,142 holders — near 3-yr low, contrarian setup
Squeeze score 61
elevated · 0–100
Fundamentals
Weak
Revenue growth −7%
Y/Y
Gross margin 144%
expanding
EPS growth −211%
Y/Y
Valuation P/E 69
rich
Buyback $4.1B
authorized
Balance sheet $2.5B
net debt
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −20%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 8
Latest guidance · from the 8-K filed Aug 4, 2026
full-year 2026
Organic sales growth at least 4%
in 2026
Amortization expense $275M
Amortization expense $1.54
Previous outlook earlier release · from the Earnings Call filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EPS · full year $2.35 – $2.40
Share repurchase (accelerated) · full year $275M
Operating EBITDA at the midpoint · full year $1.75B
Tax rate · full year 24% – 25%
Free cash flow conversion · 2026 at least 90%
Prior guidance period ended · from the Earnings Call filed Aug 4, 2026
Net sales · third quarter 2026 $1.84B
Operating EBITDA · third quarter 2026 $448M
Adjusted EPS · third quarter 2026 $1.80 – $1.90
Operating EBITDA margins · third quarter 2026 24.4%
Organic growth year over year adjusted for the prior year timing · third quarter 5%
Guided vs delivered · last 8 settled
Net sales third quarter 2026
guided $1.84B
$1.87B Beat +1.8%
Net sales first quarter 2026
guided $1.67B
$1.68B Beat +0.7%
Net sales full-year 2025
guided $6.84B
$6.85B Beat +0.1%
Net sales fourth quarter
guided $1.69B
$1.69B Beat +0.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
93% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $135 › 200d $139 — 200d above 50d
Institutional flow Distributing
1,066 of 1,142 funds reported for Sep 30 · net -2.6M sh shares · +107 new
Insider flow Distributing
Net -$14.1M over 90 days · 100% sells
Short interest Falling
2.92% of shares out · ▼ -17.4% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1,142 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $111 Now $154 · 93% Range high $157
vs 200-day avg +10% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted earnings (non-GAAP) non-GAAP $483M Six Months Ended Jun 30, 2026 —
Adjusted EPS non-GAAP $1.88 second quarter 2026 —
Adjusted free cash flow (non-GAAP) non-GAAP $454M Six Months Ended Jun 30, 2026 —
Adjusted free cash flow conversion (non-GAAP) non-GAAP 94% Six Months Ended Jun 30, 2026 —
Average price per share under Q2 2026 ASR Transaction $148.91 Q2 2026 ASR Transaction (completed May 2026) filing —
Corporate operating EBITDA -$53M Six Months Ended Jun 30, 2026 —
Diversified Industrials operating EBITDA $413M Six Months Ended Jun 30, 2026 —
Healthcare & Water Technologies operating EBITDA $502M Six Months Ended Jun 30, 2026 —
Operating EBITDA (non-GAAP) non-GAAP $862M Six Months Ended Jun 30, 2026 —
Operating EBITDA margin non-GAAP 24.6% second quarter 2026 —
Organic sales - Healthcare & Water Technologies 3% Six Months Ended June 30, 2026 —
Organic sales growth non-GAAP 4% second quarter 2026 —
Organic sales growth (Diversified Industrials) non-GAAP 3% 2Q'26 —
Shares delivered under Q2 2026 ASR Transaction 1.8M Q2 2026 ASR Transaction (completed May 2026) filing —
Total segment operating EBITDA 471M the three months ended June 30, 2026 filing —
Transaction-adjusted free cash flow (non-GAAP) non-GAAP $473M Six Months Ended Jun 30, 2026 —
Transaction-adjusted free cash flow conversion (non-GAAP) non-GAAP 98% Six Months Ended Jun 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Specialty Chemicals — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DD
DuPont de Nemours, Inc.
this stock
$20.38B — -7.1% 69.0 2.9%
LIN
Linde PLC
$241.51B +23.4% +3.0% 34.9 1.4%
AIQUF
L Air Liquide SA
$137.11B +14.4% — — 0.0%
ECL
Ecolab Inc.
$86.74B +17.8% +2.2% 42.1 1.5%
SHW
Sherwin Williams Co
$84.53B +8.0% +2.1% 32.2 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,179
% held
78.4%
Reported
1,066 of 1,142
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
726
View
Short & Settlement
Short Interest Falling
Shares short
3.9M
Days to cover
4.6d
Change
-815.4K sh
View
Short Volume
Short vol %
39%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
336
Value
$44.5K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
45.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$14.1M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Jul 17, 2026
View
Financials
Financials
Revenue (FY)
$6.8B
Net income (FY)
$-779.0M
EPS diluted
$-5.58
View
Buybacks
Authorized · 3 programs
$4.1B
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 3, 2026
This year
21

DuPont posted third-quarter 2026 net sales of $1,868 million, up 4%, adjusted EPS of $2.09 and operating EBITDA of $469 million. It raised full-year 2026 adjusted EPS guidance to $7.47 - $7.52 per share and plans a $250 million fourth-quarter share repurchase.

View
Proposed Sales
Value
$349.3K
Shares
2.3K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
DuPont Reports Third Quarter 2026…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
DD +5.0% +17.9% +3.6% +9.8% +27.5%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +2.4% +19.0% +3.1% +10.0% +16.9%

Capital returns

Latest dividend
$0.60 / share · ex Aug 31, 2026
Declared · upcoming
$0.60 / share · ex Nov 30, 2026
Raised 16.6%
Paid (TTM)
$2.40 / share · 4 payouts
Dividend yield (TTM, derived)
1.56%
Full dividend history
Buyback programs · 3 active · as of Nov 3, 2026
Authorized (total)
$4.10B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1666700 CUSIP 26614N201 13F (30d) 918 filings 833 filers Visit website Investor relations